Here, we demonstrate the preclinical efficacy of several approaches through which impairing PGRN's interaction with SORT1, a neuronal receptor that mediates PGRN endocytosis and degradation, restores extracellular PGRN levels in FTD patient-derived iPSC-neurons and lymphocytes (Fig. 6). This evidence concerns the gene SORT1 and frontotemporal dementia.